Loading...

Dynavax Technologies

DB:DYF1
Snowflake Description

High growth potential and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
DYF1
DB
$410M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The last earnings update was 51 days ago. More info.


Add to Portfolio Compare Print
  • Dynavax Technologies has significant price volatility in the past 3 months.
DYF1 Share Price and Events
7 Day Returns
-8.4%
DB:DYF1
-1.4%
DE Biotechs
2.4%
DE Market
1 Year Returns
-62.4%
DB:DYF1
-10.6%
DE Biotechs
-6.2%
DE Market
DYF1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Dynavax Technologies (DYF1) -8.4% -19.2% -39.6% -62.4% -71.5% -49.2%
DE Biotechs -1.4% 2.6% -7.7% -10.6% 54.2% 8%
DE Market 2.4% 3% 7.4% -6.2% 9.6% 14.1%
1 Year Return vs Industry and Market
  • DYF1 underperformed the Biotechs industry which returned -10.6% over the past year.
  • DYF1 underperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
DYF1
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Dynavax Technologies undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Dynavax Technologies to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Dynavax Technologies.

DB:DYF1 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9.1%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:DYF1
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 21%) (24.59%))
1.488
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.49
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.488 * 5.96%)
9.1%

Discounted Cash Flow Calculation for DB:DYF1 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Dynavax Technologies is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:DYF1 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 9.1%)
2019 -125.50 Analyst x2 -115.03
2020 -96.00 Analyst x2 -80.66
2021 -43.00 Analyst x1 -33.11
2022 33.00 Analyst x1 23.29
2023 95.00 Analyst x1 61.47
2024 159.53 Est @ 67.93% 94.61
2025 235.49 Est @ 47.62% 128.01
2026 314.15 Est @ 33.4% 156.53
2027 387.81 Est @ 23.45% 177.12
2028 451.73 Est @ 16.48% 189.10
Present value of next 10 years cash flows $601.33
DB:DYF1 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $451.73 × (1 + 0.23%) ÷ (9.1% – 0.23%)
$5,104.27
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $5,104.27 ÷ (1 + 9.1%)10
$2,136.77
DB:DYF1 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $601.33 + $2,136.77
$2,738.10
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $2,738.10 / 64.00
$42.78
DB:DYF1 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:DYF1 represents 0.87051x of NasdaqCM:DVAX
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.87051x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 42.78 x 0.87051
€37.24
Value per share (EUR) From above. €37.24
Current discount Discount to share price of €5.58
= -1 x (€5.58 - €37.24) / €37.24
85%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Dynavax Technologies is available for.
Intrinsic value
>50%
Share price is €5.58 vs Future cash flow value of €37.24
Current Discount Checks
For Dynavax Technologies to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Dynavax Technologies's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Dynavax Technologies's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Dynavax Technologies's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Dynavax Technologies's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:DYF1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.55
NasdaqCM:DVAX Share Price ** NasdaqCM (2019-04-18) in USD $6.41
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.41x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Dynavax Technologies.

DB:DYF1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:DVAX Share Price ÷ EPS (both in USD)

= 6.41 ÷ -2.55

-2.52x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dynavax Technologies is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Dynavax Technologies is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Dynavax Technologies's expected growth come at a high price?
Raw Data
DB:DYF1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.52x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
41.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Dynavax Technologies, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Dynavax Technologies's assets?
Raw Data
DB:DYF1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.00
NasdaqCM:DVAX Share Price * NasdaqCM (2019-04-18) in USD $6.41
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.85x
DB:DYF1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:DVAX Share Price ÷ Book Value per Share (both in USD)

= 6.41 ÷ 1.00

6.39x

* Primary Listing of Dynavax Technologies.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dynavax Technologies is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Dynavax Technologies's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Dynavax Technologies has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Dynavax Technologies expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
41.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Dynavax Technologies expected to grow at an attractive rate?
  • Dynavax Technologies's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Dynavax Technologies's earnings growth is expected to exceed the Germany market average.
  • Dynavax Technologies's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:DYF1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:DYF1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 41.3%
DB:DYF1 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 39%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:DYF1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:DYF1 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 255 36 2
2022-12-31 181 -19 2
2021-12-31 132 -64 2
2020-12-31 108 -96 -117 3
2019-12-31 43 -130 -150 4
DB:DYF1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 8 -131 -159
2018-09-30 3 -115 -146
2018-06-30 1 -99 -128
2018-03-31 0 -82 -109
2017-12-31 0 -78 -95
2017-09-30 8 -86 -89
2017-06-30 8 -97 -102
2017-03-31 10 -105 -111
2016-12-31 11 -107 -112
2016-09-30 4 -103 -118
2016-06-30 5 -97 -113
2016-03-31 4 -96 -108

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Dynavax Technologies's earnings are expected to grow significantly at over 20% yearly.
  • Dynavax Technologies's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:DYF1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Dynavax Technologies Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:DYF1 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.45 0.45 0.45 1.00
2022-12-31 -0.25 -0.25 -0.25 1.00
2021-12-31 -0.85 -0.85 -0.85 1.00
2020-12-31 -1.72 -1.55 -1.85 3.00
2019-12-31 -2.35 -2.05 -2.72 4.00
DB:DYF1 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.55
2018-09-30 -2.36
2018-06-30 -2.11
2018-03-31 -1.89
2017-12-31 -1.81
2017-09-30 -1.90
2017-06-30 -2.42
2017-03-31 -2.81
2016-12-31 -2.92
2016-09-30 -3.17
2016-06-30 -3.01
2016-03-31 -3.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Dynavax Technologies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Dynavax Technologies's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Dynavax Technologies has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Dynavax Technologies performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Dynavax Technologies's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Dynavax Technologies does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Dynavax Technologies's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Dynavax Technologies's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Dynavax Technologies's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Dynavax Technologies Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:DYF1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 8.20 -158.90 64.77
2018-09-30 2.90 -146.35 57.59
2018-06-30 1.49 -127.95 47.83
2018-03-31 0.34 -108.83 37.79
2017-12-31 0.33 -95.15 27.37
2017-09-30 7.60 -89.47 26.28
2017-06-30 7.71 -102.04 32.02
2017-03-31 10.25 -110.71 35.56
2016-12-31 11.04 -112.44 37.26
2016-09-30 4.44 -117.57 35.79
2016-06-30 5.46 -113.00 29.54
2016-03-31 4.37 -107.60 25.49
2015-12-31 4.05 -106.79 22.18
2015-09-30 5.64 -102.22 20.92
2015-06-30 6.66 -101.91 19.22
2015-03-31 8.16 -103.10 18.39
2014-12-31 11.03 -90.72 17.76
2014-09-30 11.60 -89.96 23.53
2014-06-30 12.32 -75.82 24.43
2014-03-31 12.66 -68.20 22.30
2013-12-31 11.25 -75.19 26.87
2013-09-30 10.21 -74.21 24.95
2013-06-30 10.16 -76.32 26.81
2013-03-31 9.45 -74.27 29.84
2012-12-31 9.71 -69.95 28.16
2012-09-30 19.34 -53.67 24.44
2012-06-30 17.64 -51.11 23.51

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Dynavax Technologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Dynavax Technologies has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Dynavax Technologies improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Dynavax Technologies's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Dynavax Technologies has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Dynavax Technologies's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Dynavax Technologies's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Dynavax Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Dynavax Technologies's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Dynavax Technologies's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Dynavax Technologies Company Filings, last reported 3 months ago.

DB:DYF1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 63.07 100.87 145.54
2018-09-30 97.01 100.32 180.22
2018-06-30 131.31 99.77 216.04
2018-03-31 165.89 99.23 250.78
2017-12-31 199.55 0.00 191.85
2017-09-30 204.43 0.00 191.68
2017-06-30 140.53 0.00 126.96
2017-03-31 97.40 0.00 85.36
2016-12-31 89.20 0.00 81.42
2016-09-30 108.27 0.00 109.55
2016-06-30 138.77 0.00 138.99
2016-03-31 164.43 0.00 166.85
2015-12-31 187.08 0.00 196.13
2015-09-30 211.19 0.00 220.70
2015-06-30 74.53 9.46 93.38
2015-03-31 75.07 9.51 97.59
2014-12-31 100.48 9.56 122.65
2014-09-30 121.58 0.00 130.57
2014-06-30 150.67 0.00 154.31
2014-03-31 173.85 0.00 177.68
2013-12-31 186.29 0.00 189.38
2013-09-30 72.40 0.00 76.47
2013-06-30 84.66 0.00 89.16
2013-03-31 97.93 0.00 105.37
2012-12-31 114.83 0.00 125.13
2012-09-30 130.06 14.45 148.28
2012-06-30 144.71 13.91 160.20
  • Dynavax Technologies's level of debt (159.9%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 159.9% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Dynavax Technologies has less than a year of cash runway based on current free cash flow.
  • Dynavax Technologies has less than a year of cash runway if free cash flow continues to grow at historical rates of 5.4% each year.
X
Financial health checks
We assess Dynavax Technologies's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Dynavax Technologies has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Dynavax Technologies's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Dynavax Technologies dividends.
If you bought €2,000 of Dynavax Technologies shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Dynavax Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Dynavax Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:DYF1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:DYF1 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Dynavax Technologies has not reported any payouts.
  • Unable to verify if Dynavax Technologies's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Dynavax Technologies's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Dynavax Technologies has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Dynavax Technologies's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Dynavax Technologies afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Dynavax Technologies has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Dynavax Technologies's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Eddie Gray
COMPENSATION $3,146,113
AGE 59
TENURE AS CEO 5.9 years
CEO Bio

Mr. Eddie Gray has been the Chief Executive Officer at Dynavax Technologies Corporation since May 1, 2013. Mr. Gray served as the President of Pharmaceuticals Europe at GlaxoSmithKline plc since December 7, 2015. He served as Member of the Pharmaceuticals Europe Executive Team of GlaxoSmithKline plc. Mr. Gray served as the President of Pharmaceuticals Europe at GlaxoSmithKline plc., since January 1, 2008. Mr. Gray served as Senior Vice President and General Manager, Pharmaceuticals UK for GlaxoSmithKline from 2001 to 2007. Mr. Gray joined SmithKline Beecham in 1988 and served as National Sales Manager. He held various positions in the UK company of increasing responsibility, including Head of Hospital Sales, Marketing Manager for Anti-Infective products and Business Unit Director for the UK Pharmaceuticals General Medicine business before moving to the US, where he assumed responsibility of Market Research for the US Pharmaceuticals business. Mr. Gray also served as Vice President and Director of Anti-Infectives Marketing of SmithKline Beecham, then Vice President and Director of Vaccines Business Unit in the US and also served as Vice President and General Manager of SmithKline Beecham Pharmaceuticals, Canada, where he served as Member of SmithKline Beecham's Executive Management Team for North America. Mr. Gray serves on the Board of Management of the Association of the British Pharmaceutical Industry (ABPI) and chairs the ABPI Economic Strategy Group. Mr. Gray serves as Advisory Board Member of Opportunity Now, an organisation for employers who are committed to creating an inclusive workplace for women; and a Trustee of Project HOPE UK which aims to make health care available for people around the globe, especially children. He has been Director at Dynavax Technologies Corporation since May 1, 2013. Mr. Gray holds an honours degree in Chemistry and Management Studies from the University of London and an MBA from the Cranfield School of Management in the UK. Mr. Gray holds a Degree in Chemistry and Management Studies from the University of London and MBA from the Cranfield School of Management in the UK.

CEO Compensation
  • Eddie's compensation has increased whilst company is loss making.
  • Eddie's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Dynavax Technologies management team in years:

5.8
Average Tenure
64
Average Age
  • The average tenure for the Dynavax Technologies management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Eddie Gray

TITLE
CEO & Director
COMPENSATION
$3M
AGE
59
TENURE
5.9 yrs

Dennis Carson

TITLE
Co-Founder
COMPENSATION
$69K
AGE
71

Michael Ostrach

TITLE
CFO, Chief Business Officer & Senior VP
COMPENSATION
$2M
AGE
66
TENURE
4.1 yrs

David Novack

TITLE
Senior Vice President of Operations & Quality
COMPENSATION
$2M
AGE
56
TENURE
6.1 yrs

Bob Coffman

TITLE
Chief Scientific Officer & Senior VP
COMPENSATION
$2M
AGE
71
TENURE
18.3 yrs

Rob Janssen

TITLE
Chief Medical Officer & Senior VP of Clinical Development
COMPENSATION
$2M
AGE
64
TENURE
5.8 yrs

David Johnson

TITLE
VP & Chief Accounting Officer
AGE
64
TENURE
5.2 yrs

Heather Rowe

TITLE
Vice President of Investor Relations & Corporate Communications
TENURE
0.3 yrs

Steven Gersten

TITLE
Chief Ethics & Compliance Officer
TENURE
4.3 yrs

Cecilia Vitug

TITLE
Vice President of Human Resources
TENURE
12.5 yrs
Board of Directors Tenure

Average tenure and age of the Dynavax Technologies board of directors in years:

7.3
Average Tenure
71
Average Age
  • The tenure for the Dynavax Technologies board of directors is about average.
Board of Directors

Arnie Oronsky

TITLE
Chairman
COMPENSATION
$102K
AGE
79
TENURE
13.2 yrs

Eddie Gray

TITLE
CEO & Director
COMPENSATION
$3M
AGE
59
TENURE
5.9 yrs

Dennis Carson

TITLE
Co-Founder
COMPENSATION
$69K
AGE
71
TENURE
21.3 yrs

Peggy Phillips

TITLE
Director
COMPENSATION
$92K
AGE
64
TENURE
12.7 yrs

Dan Kisner

TITLE
Director
COMPENSATION
$86K
AGE
71
TENURE
8.8 yrs

Laura Brege

TITLE
Director
COMPENSATION
$89K
AGE
60
TENURE
4.2 yrs

Stanley Plotkin

TITLE
Member of Scientific Advisory Board
COMPENSATION
$69K
AGE
85
TENURE
0.8 yrs

Francis Cano

TITLE
Director
COMPENSATION
$81K
AGE
71
TENURE
9.4 yrs

Natale Ricciardi

TITLE
Director
COMPENSATION
$74K
AGE
69
TENURE
5.8 yrs

Laura Q. Chow

TITLE
Member of Scientific Advisory Board
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • Dynavax Technologies insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
02. Mar 19 Sell David Johnson Individual 28. Feb 19 28. Feb 19 -20,765 €7.93 €-164,651
02. Mar 19 Sell Robert Coffman Individual 28. Feb 19 28. Feb 19 -63,202 €7.93 €-501,144
02. Mar 19 Sell Michael Ostrach Individual 28. Feb 19 28. Feb 19 -31,694 €7.82 €-247,691
08. Dec 18 Sell Francis Cano Individual 06. Dec 18 06. Dec 18 -2,000 €9.21 €-18,416
08. Jun 18 Sell Michael Ostrach Individual 08. Jun 18 08. Jun 18 -4,000 €13.20 €-52,804
X
Management checks
We assess Dynavax Technologies's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Dynavax Technologies has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Its product candidates include SD-101, a cancer immunotherapy that is in Phase 2 clinical trials; DV281, an investigational TLR9 agonist, which is in Phase I clinical trial for the treatment of non-small cell lung cancer; and AZD1419, which is in Phase IIa clinical trial to treat asthma. Dynavax Technologies Corporation has a collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for various immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.

Details
Name: Dynavax Technologies Corporation
DYF1
Exchange: DB
Founded: 1996
$364,767,801
63,996,911
Website: http://www.dynavax.com
Address: Dynavax Technologies Corporation
2929 Seventh Street,
Suite 100,
Berkeley,
California, 94710,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM DVAX Common Stock Nasdaq Capital Market US USD 19. Feb 2004
DB DYF1 Common Stock Deutsche Boerse AG DE EUR 19. Feb 2004
LSE 0IDA Common Stock London Stock Exchange GB USD 19. Feb 2004
Number of employees
Current staff
Staff numbers
249
Dynavax Technologies employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 20:56
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/03
Last earnings filing: 2019/02/27
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.